MLH3 and malignant colon neoplasm: This redundancy also may help to explain the low prevalence and penetrance of PMS2 mutations in MMR-deficient colon cancers (Lynch and de la Chapelle 2003) and the reported lack of biochemical data to support MLH3 in Lynch syndrome (Ou et al. 2009).